| Preface |
|
iii | |
| Contributors |
|
x | |
| Part I: Introduction to Vaccinology |
|
|
Vaccines and Vaccination in Historical Perspective |
|
|
1 | (12) |
|
|
|
|
|
|
|
|
|
|
|
The Traditional Vaccines: An Overview |
|
|
13 | (12) |
|
|
|
|
|
|
An Overview of Biotechnology as Applied to Vaccine Development |
|
|
25 | (10) |
|
|
|
|
|
|
Initial Clinical Evaluation of New Vaccine Candidates: Phase 1 and 2 Clinical Trials of Safety, Immunogenicity, and Preliminary Efficacy |
|
|
35 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term Evaluation of Vaccine Protection: Methodological Issues for Phase 3 Trials and Phase 4 Studies |
|
|
47 | (22) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Economic Analyses of Vaccines and Vaccination Programs: Evaluating the Economic Rationale for Immunization |
|
|
69 | (10) |
|
|
|
|
|
|
|
|
|
|
|
Reaping the Benefits: Getting Vaccines to Those Who Need Them |
|
|
79 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Progress and Challenges in Modern Vaccinology: An Immunologist's Perspective |
|
|
89 | (4) |
|
|
|
|
|
|
The Eradication of Vaccine-Preventable Diseases |
|
|
93 | (6) |
|
|
|
|
|
| Part II: Molecular Immunology as Applied to Vaccine Development |
|
|
Recent Advances in Immunology: Impact on Vaccine Development |
|
|
99 | (28) |
|
|
|
|
|
|
|
|
|
|
|
Computer Prediction of T-Cell Epitopes |
|
|
127 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Identification of B- and T-Cell Epitopes Through Structural Characterization and Peptide Technology |
|
|
139 | (12) |
|
|
|
|
|
|
|
|
|
|
|
The Gastrointestinal Mucosal Immune System |
|
|
151 | (22) |
|
|
|
|
|
| Part III: Immunopotentiation, Adjuvants, Nonliving Antigen Delivery Systems, and ``Naked DNA'' Vaccines |
|
|
|
|
173 | (20) |
|
|
|
|
|
|
Proteosomes for Improved Nasal, Oral, or Injectable Vaccines |
|
|
193 | (14) |
|
|
|
|
|
|
Liposomes as Adiuvants for Vaccines |
|
|
207 | (8) |
|
|
|
|
|
|
Prospects for the Development of New and Improved Vaccines Through the Use of Microencapsulation Technology |
|
|
215 | (14) |
|
|
|
|
|
|
Antigen Cochleate Preparations for Oral and Systemic Vaccination |
|
|
229 | (10) |
|
|
|
|
|
|
|
|
|
|
|
Ty Virus-like Particles as an Antigen Delivery System |
|
|
239 | (8) |
|
|
|
|
|
|
Immunopotentiating Reconstituted Influenza Virosomal Vaccine Delivery System |
|
|
247 | (6) |
|
|
|
|
|
|
|
|
|
|
|
Mutant Pertussis and Escherichia coli Heat-Labile Toxins as Adjuvants for Enhancing Local and Systemic Immune Responses to Coadministered, Nonliving Antigens |
|
|
253 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oral Vaccine Production in the Edible Tissues of Transgenic Plants |
|
|
263 | (16) |
|
|
|
|
|
|
|
|
|
|
|
DNA-Based Vaccines: Extending the Technology |
|
|
279 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccination Against Influenza with Plasmid DNA: Cross-Strain and Homologous Protection |
|
|
287 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Part IV: Live Antigen Delivery Systems |
|
|
Vaccinia Virus as a Live Vector for Expression of Immunogens |
|
|
297 | (18) |
|
|
|
|
|
|
|
|
|
|
|
Attenuated Poliovirus as Live Vector |
|
|
315 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Attenuated Salmonella as a Live Vector for Expression of Foreign Antigens |
|
|
331 | (32) |
|
Expressing Bacterial Antigens |
|
|
331 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
343 | (8) |
|
|
|
|
|
|
Salmonella Expressing Protozoal Antigens |
|
|
351 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BCG as a Recombinant Vaccine Vector |
|
|
363 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Attenuated Vibrio cholerae as a Live Vector for Expression of Foreign Antigens |
|
|
379 | (8) |
|
|
|
|
|
|
|
|
|
|
| Part V: New and Improved Vaccines Against Diseases for Which There Already Exist Licensed Vaccines |
|
|
New and Improved Vaccines Against Pertussis |
|
|
387 | (30) |
|
|
|
|
|
|
|
|
|
|
|
New and Improved Vaccines Against Diphtheria and Tetanus |
|
|
417 | (20) |
|
|
|
|
|
|
Progress in Development of New Attenuated Strains of Salmonella typhi as Live Oral Vaccines Against Typhoid Fever |
|
|
437 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Improved Vaccines Against Cholera |
|
|
447 | (22) |
|
Attenuated Vibrio cholerae 01 and 0139 Strains as Live Oral Cholera Vaccines |
|
|
447 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oral B Subunit Killed Whole-Cell Cholera Vaccine |
|
|
459 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Improved Vaccines Against Meningococcal Disease |
|
|
469 | (20) |
|
|
|
|
|
|
Epidemiological Impact of Conjugate Vaccines on Invasive Disease Caused by Haemophilus influenzae Type b |
|
|
489 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conjugate Vaccines Against Streptococcus pneumoniae |
|
|
503 | (24) |
|
|
|
|
|
|
|
|
|
|
|
Vaccine Development for Rickettsial Infections: Rocky Mountain Spotted Fever, Epidemic Typhus, and Scrub Typhus |
|
|
527 | (18) |
|
|
|
|
|
|
|
|
|
|
|
New and Improved Vaccines Against Influenza |
|
|
545 | (26) |
|
|
|
|
|
|
|
|
|
|
|
New Vaccines Against Hepatitis A |
|
|
571 | (16) |
|
|
|
|
|
|
|
|
|
|
|
New and Improved Vaccines for Dengue, Japanese Encephalitis, and Yello Fever Viruses |
|
|
587 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Improved Vaccines Against Rabies |
|
|
607 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Combination Vaccines for Routine Infant Immunization: Prospects, Progress, and Dilemmas |
|
|
619 | (12) |
|
|
|
|
|
|
|
|
|
|
|
New Vaccines Against Tuberculosis |
|
|
631 | (16) |
|
|
|
|
|
|
|
|
|
|
|
Live Attenuated Varicella Vaccines |
|
|
647 | (12) |
|
|
|
|
|
|
|
|
|
|
| Part VI: Vaccines Against Diseases for Which Licensed Vaccines Have Not Previously Been Available (or Which Have Not Been Widely Licensed) |
|
|
Vaccines Against Rotavirus |
|
|
659 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Experimental HIV-1 Vaccines |
|
|
673 | (38) |
|
|
|
|
|
|
Vaccines Against Respiratory Syncytial Virus and Parainfluenza Virus Type 3 |
|
|
711 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
727 | (22) |
|
|
|
|
|
|
Vaccines Against Arenaviruses and Filoviruses |
|
|
749 | (18) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Papillomavirus Infections |
|
|
767 | (16) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Streptococcus pyogenes Infections |
|
|
783 | (20) |
|
|
|
|
|
|
|
|
|
|
|
O-Specific Polysaccharide--Protein Conjugates for Prevention of Enteric Bacterial Diseases |
|
|
803 | (14) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Gonococcal Infection |
|
|
817 | (26) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Shigella Infections |
|
|
843 | (22) |
|
Escherichia coli- or Salmonella typhi-Expressing Shigella Antigens |
|
|
843 | (10) |
|
|
|
|
|
|
|
|
|
|
|
Engineered Attenuated Mutants of Shigella as Live Oral Vaccines |
|
|
853 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Enterotoxigenic Escherichia coli Infections |
|
|
865 | (20) |
|
Oral Inactivated Vaccines Against Enterotoxigenic Escherichia coli |
|
|
865 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Live Oral Vaccines and Subunit (Purified Fimbriae and Toxin Subunit) Vaccines |
|
|
875 | (10) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Campylobacter jejuni |
|
|
885 | (12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Lyme Disease |
|
|
897 | (16) |
|
|
|
|
|
|
Vaccines Against Dental Caries Infection |
|
|
913 | (18) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Klebsiella, Pseudomonas, and Septicemic E. coli Infections |
|
|
931 | (14) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Escherichia coli and Proteus Urinary Tract Infections |
|
|
945 | (18) |
|
|
|
|
|
|
Vaccines Against Helicobacter pylori |
|
|
963 | (16) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines for Staphylococcus aureus Infections |
|
|
979 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
989 | (76) |
|
Synthetic Peptide Vaccines Against the Sporozoite Stage of Plasmodium |
|
|
989 | (20) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Designed to Induce Protective T-Cell Responses Against Plasmodium-Infected Hepatocytes |
|
|
1009 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spf66 Vaccine Against Asexual Erythrocytic Stages of P. falciparum |
|
|
1027 | (8) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Asexual Blood Stages of Plasmodium falciparum |
|
|
1035 | (22) |
|
|
|
|
|
|
Vaccines Against Sexual-Stage Parasites of P. falciparum: Transmission-Blocking Vaccines |
|
|
1057 | (8) |
|
|
|
|
|
|
Vaccines Against Leishmaniasis |
|
|
1065 | (16) |
|
|
|
|
|
|
|
|
|
|
|
Vaccines Against Schistosomiasis |
|
|
1081 | (14) |
|
|
|
|
|
|
|
|
|
|
| Part VII: Vaccines Against Chronic Diseases, Vaccine Therapy, and Miscellaneous Vaccines |
|
|
|
|
1095 | (22) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1117 | (14) |
|
|
|
|
|
|
Vaccines to Prevent Pregnancy |
|
|
1131 | (14) |
|
|
|
|
|
|
|
|
|
|
|
An Anti-arthropod Vaccine: TickGARD---A Vaccine to Prevent Cattle Tick Infestations |
|
|
1145 | (8) |
|
|
|
|
|
| Part VIII: Commercial and Regulatory Aspects of Vaccine Production and Distribution |
|
|
Large-Scale Production of Live Attenuated Bacterial and Viral Vaccines |
|
|
1153 | (12) |
|
|
|
|
|
|
|
|
|
|
|
Vaccine Development: The Long Road from Initial Idea to Product Licensure |
|
|
1165 | (14) |
|
|
|
|
|
|
Inadvertant Nontarget Effects of Live Vaccines |
|
|
1179 | (6) |
|
|
|
|
|
|
|
|
|
|
|
The Role of the Food and Drug Administration in Vaccine Testing and Licensure |
|
|
1185 | (10) |
|
|
|
|
|
|
|
|
|
|
| Index |
|
1195 | |
Shopping Cart
![Soaring Scores in Integrated Language Arts: Level H [With Answer Key]](http://images.ecampus.com/images/t/6/035/9780739816035.jpg)
